Galectin Therapeutics
GALT
86 hedge funds and large institutions have $22.2M invested in Galectin Therapeutics in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 21 closing their positions.
75% more capital invested
Capital invested by funds: $12.7M → $22.2M (+$9.49M)
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
0.06% less ownership
Funds ownership: 16.67% → 16.61% (-0.06%)
8% less funds holding
Funds holding: 93 → 86 (-7)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
66% less call options, than puts
Call options by funds: $355K | Put options by funds: $1.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$1.12M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$272K |
| 3 |
LPL Financial
San Diego,
California
|
+$260K |
| 4 |
Millennium Management
New York
|
+$216K |
| 5 |
VCM
Vivaldi Capital Management
Chicago,
Illinois
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$783K |
| 2 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$639K |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$287K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$279K |
| 5 |
AWS
Atria Wealth Solutions
New York
|
-$227K |
GALT Hedge Fund Activity: Q2 2025 in Review
86 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2025, worth a combined $22.2M — up 75% from $12.7M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of GALT and 15 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 25 added.
The largest buyer was Jane Street, opening a new position worth an estimated $1.12M. The largest seller was BlackRock, cutting an estimated $783K.
- 86 institutional investors held Galectin Therapeutics (GALT) as of Q2 2025, down from 93 in Q1 2025.
- Funds reported $22.2M of Galectin Therapeutics stock for Q2 2025, up 75% quarter-over-quarter.
- 15 funds opened new Galectin Therapeutics positions in Q2 2025 and 21 closed out, a net change of -6 holders.
- The largest Galectin Therapeutics buyer in Q2 2025 was Jane Street, an estimated $1.12M added.
- The largest Galectin Therapeutics seller in Q2 2025 was BlackRock, an estimated $783K sold.
Based on aggregated 13F filings for Q2 2025.